Polymalic Acid Nanoconjugate for Targeted Temozolomide Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for malignant gliomas, such as surgery, radiation, and chemotherapy with Temozolomide (TMZ), face limitations including toxicity, tumor resistance, and poor survival rates, necessitating a novel drug delivery system that enhances tumor targeting, solubility, and apoptosis induction while minimizing general toxicity and overcoming multidrug resistance.
Innovation Solution
A drug delivery system comprising a polymalic acid platform conjugated with a trileucine (LLL) moiety and targeting antibodies, such as anti-transferrin receptor (TfR) antibodies, to create a multifunctional nanoconjugate of TMZ, which includes PEG for protection and pH-dependent endosomal membrane disruption, allowing for targeted and efficient delivery of TMZ to tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Temozolomide (TMZ) is used as a chemotherapeutic agent, then tumor cell killing is improved, but general toxicity increases
Solution Approach 1:
The patent segments the drug delivery system into distinct functional components: a polymalic acid platform for drug conjugation, PEG chains for steric protection and solubility, and targeting ligands (such as transferrin receptor antibodies) for tumor-specific recognition. This segmentation allows the drug to be delivered selectively to tumor cells while protecting healthy tissues from toxicity.
Solution Approach 2:
The patent introduces a polymalic acid-PEG-conjugate as an intermediary carrier that mediates between the toxic chemotherapeutic agent TMZ and the target tumor cells. This intermediary system enables targeted delivery through receptor-mediated endocytosis, reducing direct exposure of healthy tissues to the toxic drug while maintaining effective concentration at the tumor site.
2Reliability
If TMZ dosage is increased to overcome tumor resistance, then therapeutic efficacy is improved, but toxicity increases
Solution Approach 1:
The patent employs feedback mechanisms through the use of tumor-specific targeting ligands that recognize and bind to overexpressed receptors on tumor cells (such as transferrin receptor). This feedback system ensures that the drug is selectively activated at the tumor site, allowing for effective dosing without proportional increases in systemic toxicity, thereby overcoming tumor resistance while maintaining safety.
Solution Approach 2:
The patent applies local quality by concentrating the therapeutic effect specifically at the tumor site through targeted delivery. The polymalic acid conjugate system exhibits different properties in different locations: it remains stable and protected in circulation, then undergoes specific recognition and internalization at tumor cells, creating localized high-concentration drug effect without systemic toxicity escalation.
3Ease of operation
If conventional chemotherapy is used, then treatment simplicity is maintained, but tumor targeting is poor
Solution Approach 1:
The patent creates a multifunctional polymalic acid conjugate system that simultaneously provides: (1) drug loading and delivery, (2) steric protection via PEG, (3) tumor targeting via ligand-receptor interaction, and (4) endosomal escape capability. This multi-functionality is achieved within a single conjugate structure, maintaining relative treatment simplicity while dramatically improving tumor targeting compared to conventional chemotherapy.
Solution Approach 2:
The patent utilizes composite material construction by combining polymalic acid platform with PEG chains and targeting ligands to create a hybrid conjugate system. This composite structure integrates the benefits of each component: the polymalic acid provides drug conjugation capability, PEG provides protection and solubility, and the targeting ligand provides specificity, achieving superior tumor targeting while maintaining ease of administration.
4Quantity of substance
If TMZ is administered systemically, then broad coverage is achieved, but accumulation in solid tumors is limited
Solution Approach 1:
The patent applies preliminary action by pre-equipping the drug carrier with tumor-specific targeting ligands (such as transferrin receptor antibodies or peptides) before administration. This preliminary functionalization enables the systemic circulation to be converted into targeted delivery, where the conjugate naturally accumulates at tumor sites through receptor-mediated endocytosis, achieving both broad coverage and high tumor accumulation simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoconjugate effectively reduces cancer cell viability, including TMZ-resistant cell lines, by facilitating receptor-mediated endocytosis and endosomal escape, thereby enhancing the therapeutic efficacy of TMZ while minimizing side effects and improving treatment outcomes.
Implementation Method 1
facilitating receptor-mediated endocytosis
Implementation Method 2
pH-dependent endosomal membrane disruption
Implementation Method 3
pH-dependent endosomal membrane disruption
Data Source
Figure 1
Figure 2a~2b
Figure 3
AI summary
The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety. The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a multifunctional nanoconjugate of temozolomide (TMZ) by conjugating TMZ in its hydrazide form to a polymalic acid platform. In another embodiment, the polymalic acid platform is conjugated to a monoclonal antibody to transferrin receptor, a trileucine (LLL) moiety, and/or a polyethylene glycol (PEG) moiety.